Literature DB >> 11543683

Identification of alkylidene hydrazides as glucagon receptor antagonists.

A Ling1, Y Hong, J Gonzalez, V Gregor, A Polinsky, A Kuki, S Shi, K Teston, D Murphy, J Porter, D Kiel, J Lakis, K Anderes, J May, L B Knudsen, J Lau.   

Abstract

High throughput screening of our small molecule combinatorial library identified a class of benzoylnaphthalenehydrazones with modest affinity for the human glucagon receptor. Optimization of this initial hit through a series of targeted libraries and traditional medicinal chemistry led to ligands with nanomolar affinities. Pharmacological evaluation demonstrated that these ligands were competitive glucagon receptor antagonists. Intravenous administration of a representative benzoylnaphthalenehydrazone into rats attenuated glucagon-stimulated glucose levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11543683     DOI: 10.1021/jm000547o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes?

Authors:  K G Murphy; S R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-09       Impact factor: 11.205

2.  Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis.

Authors:  Tom Kirchhausen; Eric Macia; Henry E Pelish
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

3.  Development of novel Asf1-H3/H4 inhibitors.

Authors:  Greg F Miknis; Sarah J Stevens; Luke E Smith; David A Ostrov; Mair E A Churchill
Journal:  Bioorg Med Chem Lett       Date:  2014-12-04       Impact factor: 2.823

4.  Small-molecule agonists for the glucagon-like peptide 1 receptor.

Authors:  Lotte Bjerre Knudsen; Dan Kiel; Min Teng; Carsten Behrens; Dilip Bhumralkar; János T Kodra; Jens J Holst; Claus B Jeppesen; Michael D Johnson; Johannes Cornelis de Jong; Anker Steen Jorgensen; Tim Kercher; Jarek Kostrowicki; Peter Madsen; Preben H Olesen; Jacob S Petersen; Fritz Poulsen; Ulla G Sidelmann; Jeppe Sturis; Larry Truesdale; John May; Jesper Lau
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-09       Impact factor: 11.205

5.  Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice.

Authors:  J Mu; G Jiang; E Brady; Q Dallas-Yang; F Liu; J Woods; E Zycband; M Wright; Z Li; K Lu; L Zhu; X Shen; R Sinharoy; M L Candelore; S A Qureshi; D-M Shen; F Zhang; E R Parmee; B B Zhang
Journal:  Diabetologia       Date:  2011-06-22       Impact factor: 10.122

6.  Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia.

Authors:  S L Conarello; G Jiang; J Mu; Z Li; J Woods; E Zycband; J Ronan; F Liu; R Sinha Roy; L Zhu; M J Charron; B B Zhang
Journal:  Diabetologia       Date:  2006-11-28       Impact factor: 10.122

Review 7.  Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Clin Sci (Lond)       Date:  2007-08       Impact factor: 6.124

8.  Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus.

Authors:  Mohamed Lotfy; Huba Kalasz; Gyorgy Szalai; Jaipaul Singh; Ernest Adeghate
Journal:  Open Med Chem J       Date:  2014-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.